Advertisement

Haemorrhages and anticoagulants the responsibility of the patient

  • F. Toulemonde

Abstract

Even using sophisticated methods like monograms for heparin and (INR-ISI) system for OA, the risk of bleeding persists during antithrombotic treatments. In most of the cases, it is reported to an overdosage, and that is true in some cases.

Keywords

International Normalise Ratio Major Bleeding Anticoagulant Therapy Heparin Therapy Heparin Prophylaxis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Albada J, Nieuwenhuis HK, Sixma JS. Treatment of acute venous thrombo-embolism with low molecular weight heparin (fragmin) — Results of a double-blind randomized study. Circulation 4, 935–940, 1980.Google Scholar
  2. 2.
    Arcelus JI, Caprini JA, Traverso CI. International perspective on venous thromboembolism prophylaxis in surgery. Semin Thromb Haemostas 4, 17, 322–325, 1991.CrossRefGoogle Scholar
  3. 3.
    Biemer JJ. Control of oral anticoagulant therapy. Ann Clin Lab Sei 18, 6, 421–428, 1988.Google Scholar
  4. 4.
    Conti S. Letter to editor. The West J Med 137(1), 81, 1982.Google Scholar
  5. 5.
    Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, Segrestaa JM. Prevention of deep venous thrombosis in elderly medical patients by a low molecular weight heparin: a randomized double blind trial. Haemostasis 16, 159–164, 1986.PubMedGoogle Scholar
  6. 6.
    Demichelis C, Cohen S, Braguer D, Juhan-Vague I, Aillaud MF. Utilité de la surveillance biologique de 1’héparinothérapie à visée curative. J Pharm Clin 3, 3–4, 367–373, 1984.Google Scholar
  7. 7.
    Derlon A, Fressinger JN. Coordinators. Utilisation des antivitamines K en pratique médicale courante. Recommandations du GEHT. STV (Suppl 3), 5, 11–15, 1991. Google Scholar
  8. 8.
    Deykin D, Salzman EW, Mayer R. Prospective study of complications of heparin therapy ISTH Congres — Washington D.C. 1972. Google Scholar
  9. 9.
    Doutemepuich C, Toulemonde F, Bousquet F, Bonini F. Comparison of the haemorragic effects of unfractionated heparin and a low molecular weight heparin fraction, CY 216, in rabbits. Thromb Res 43, 691–695, 1986.CrossRefGoogle Scholar
  10. 10.
    Etude Multicentrique Francaises. Traitement des thromboses veineuses profondes constituées — Etude comparative d’un fragment d’;heparine de bas poids moleculaire (fragmine) par voie SC et de 1’héparine standard administrée par voie veineuse continue. Rev Med Interne 10, 375–381, 1989. CrossRefGoogle Scholar
  11. 11.
    Faivre R, Neuhart Y, Kieffer Y, Apfel F, Magnin D, Didier D, Toulemonde F, Bassand JP, Maurat JP. Un nouveau traitement des thromboses veineuses profondes, les fractions d’héparine de bas poids moléculaire — Etude randomisée. Presse Med 17, 197–200, 1988.PubMedGoogle Scholar
  12. 12.
    Forfar JC. A 7 year analysis of haemorrhage in patients on long term anticoagulant treatment Biol Mol J 42, 128–132, 1979. Google Scholar
  13. 13.
    Franke CL, de Jonge J, van Swieten JC, OP de Coul AAW, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke 21(5), 726–730, 1990.Google Scholar
  14. 14.
    Glazier RL, Crowell EB. Randomized prospective trial of continuous versus intermittent heparin therapy. JAMA 236(12), 1365–1367, 1976.PubMedCrossRefGoogle Scholar
  15. 15.
    Harenberg J, Huck K, Bratsch H, Stehle G, Dempfe CE, Mall K, Blauth M, Vsadel KH, Heene DL. Therapeutic application of subcutaneous LMWH heparin in acute venous thrombosis. Haemostasis 20 (Suppl 1), 205–219, 1990.PubMedGoogle Scholar
  16. 16.
    Harenberg J, Leber G, Dempfle CE, Heene DL, Zimmermann R, Kubler W. Long term anticoagulation with low molecular weight heparin in out patients with side effects on oral anticoagulants. Nouv Rev Fr Hematol 31, 363–369, 1989.PubMedGoogle Scholar
  17. 17.
    Heiden D, Rodvier R, Harold Mielke C Heparin bleeding, platelet dysfunction and aspirin. JAMA 216(4), 330–333, 1981.CrossRefGoogle Scholar
  18. 18.
    Hirsh J, Levine MN. Low molecular weight heparin. Blood 79(1), 1–18, 1992.PubMedGoogle Scholar
  19. 19.
    Hirsh J. Oral anticoagulant drugs. N Engl J Med 324, 1865–1875, 1991.PubMedCrossRefGoogle Scholar
  20. 20.
    Hoek J, Nurmohamed MT, Ten Cate H, Ten Cate JW, Buller HR. Prevention of deep vein thrombosis following total hip replacement by a low-molecular-weight heparinoid (Org 10172). Thromb Haemost 62, 520 (Abstr.), 1989. Google Scholar
  21. 21.
    Hull R, Hirsh J, Jay R, Carter C, England C Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med 307, 1676–1681, 1982.PubMedCrossRefGoogle Scholar
  22. 22.
    Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 92(2), 375–515, 1989.Google Scholar
  23. 23.
    ICTH-ISTH. Report of the expert panel on oral anticoagulant control. Thromb Haemost 42, 1073–1114, 1979. Google Scholar
  24. 24.
    Kher A, Toulemonde F. Examen simplifié de l’hémostase in pré-operatoire. Gaz Med de France 81, 1877–1883, 1974.Google Scholar
  25. 25.
    Landefeld C, S Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 82, 703–713, 1987.Google Scholar
  26. 26.
    Landefeld CS, Goldman L. Major bleeding in out patients treated with Warparin: incidence and prediction by factors known at the start of out patient therapy. Am J Med 87, 144–152, 1989.PubMedCrossRefGoogle Scholar
  27. 27.
    Landefeld CS, McGuire E, Rosenblatt MW. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 89, 569–578, 1990.PubMedCrossRefGoogle Scholar
  28. 28.
    Landefeld CS, Rosenblatt MW. Bleeding in out patients heated with Warparin: relation to the prothrombin time and important remediable lesions. Am J Med 87, 153–159, 1989.PubMedCrossRefGoogle Scholar
  29. 29.
    Lassen MR, Borris LC, Christiansen HM, Schott P, Olsen AD, Sorensen JV, Rahr H, Jensen HP. Clinical trials with low molecular weight heparins in the prevention of postoperative thrombo-embolic complications — A meta analysis. Semin. Thromb Haemost 17(Suppl 3), 284–290, 1991.Google Scholar
  30. 30.
    Launbjerg J, Egeblad H, Heaf J, Nielsen NH. Bleeding complications to oral anticoagulant therapy: mulivariate analysis of 1010 treatment years in 551 out patients. J Int Med 229, 351–3555, 1991.CrossRefGoogle Scholar
  31. 31.
    Levine MN, Hirsh J. Hemorrhagic complications of anticoagulant therapy. Semin Thromb Haemostas 12(1), 39–57, 1986.CrossRefGoogle Scholar
  32. 32.
    Levine MN, Hirsh J, Kelton JG. Heparin induced bleeding. In: Lane D, Lindhahl U (Eds). Heparin: — Chemical and Biol, properties, — Clinical applications. E. Arnold, London, pp 517–531. 1989. Google Scholar
  33. 33.
    Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long term anticoagulant therapy. Chest 89(2), 163–255, 1986.CrossRefGoogle Scholar
  34. 34.
    Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long term anticoagulant therapy. Chest 95(2), 265–365, 1989.Google Scholar
  35. 35.
    Mant MJ, O Brien BD, Thong KL, Hammond GW et al. Haemorrhagic complications of heparin therapy. Lancet 8022, 1133–1136, 1977.Google Scholar
  36. 36.
    Morabia A. Heparin doses and major bleedings. Lancet 1, 8492, 1278–1279, 1986.PubMedCrossRefGoogle Scholar
  37. 37.
    Mottironi SC, Selz Y. Hypersensibilité à l’héparine ou le Chirurgien et les hématomes. Med et Hyg 43, 2659–2660, 1985.Google Scholar
  38. 38.
    Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification for risk factors for bleeding during treatment of acute venous thrombo-embolism with heparin or LMWH. Blood 78(9), 2337–2343, 1991.PubMedGoogle Scholar
  39. 39.
    Nitter-Hange S, Dale J. High complication and failure rates of anticoagulant therapy are unavoidable. Z Kardiologie 75(Suppl 2), 293–297, 1986.Google Scholar
  40. 40.
    Ockelford PA, Kesteren PJ, Patterson J, Brand N, Johns A. A double blind placebo controlled trial to study the efficacy and safety of a low molecular weight heparin fragment (Fragmin) in patients having major elective hip surgery. Thromb Res (Suppl. VII-B) 23, 19, 1987. CrossRefGoogle Scholar
  41. 41.
    Ockelford PA, Patterson J, John AS. A double blind randomized placebo controlled trial of thrombo-prophylaxis in major elective general surgery using once daily injections of LMW heparin fragment (Fragmin). Thromb Haemostas 62(4), 1046–1049, 1989.Google Scholar
  42. 42.
    Petitti DB, Storm BL, Melmon KL. Duration of Warparin anticoagulant therapy and the probabilities of recurrent thrombo-embolism and hemorrhage. Am J Med 81, 225–259, 1986.CrossRefGoogle Scholar
  43. 43.
    Peyman M. The significance of hemorrhage during the treatment with Coumarin anticoagulants. Acta Med Scand 162, 339, 1–62, 1958.CrossRefGoogle Scholar
  44. 44.
    Pezzuoli G, Neri Serneri GG, Settembrini PG, STEP Study Group. Effectiveness and safety of the LMWH CY 216 in the prevention of fatal pulmonary embolism and thrombo-embolic death in general surgery. Haemostasis 20(Suppl 1), 193–204, 1990. PubMedGoogle Scholar
  45. 45.
    Pollard JW, Hamilton MJ, Christensen NA, Achor RWP. Problems associated with long-term anticoagulant therapy. Circulation 25, 311–317, 1962.PubMedGoogle Scholar
  46. 46.
    Samama CM. Bilan d’;hémostase pré-opératoire: Quoi de neuf? JEPU — Arnette Paris 105–112, 1990. Google Scholar
  47. 47.
    Shetty HGM, Backhouse G, Bentley DP, Routledge PA. Effective reversal of Warpar in-induced excessive ant icoagu1at ion with low dose vitamin Kl. Thromb Haemost 67(1), 13–15, 1992.PubMedGoogle Scholar
  48. 48.
    Torholm C, Broeng L, Seest Jorgensen P et al. Thromboprophylaxis by low—molecular—weight heparin in elective hip surgery. J Bone Joint Surg (Br) 73, 434–438, 1991. Google Scholar
  49. 49.
    Toulemonde F. Can the bleeding potential of low molecular weight heparins be assessed and minimized in post surgery prophylaxis ? Semin Thromb Haemostas 17(Suppl 4), 351–356, 1991.CrossRefGoogle Scholar
  50. 50.
    Turpie A, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. Arandomized controlled trial of a low molecular weight heparin (Enoxaparine) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 315, 925–929, 1986.PubMedCrossRefGoogle Scholar
  51. 51.
    Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA 244(11), 1209–1212, 1980.PubMedCrossRefGoogle Scholar
  52. 52.
    Watson CJE, Deane AM, Doyle PT, Bullock KN. Identifiable factors in post-prostatectomy haemorrhage: the role of aspirin Brit J Urol 66, 85–87, 1990.Google Scholar
  53. 53.
    Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. Am Heart J 77(2), 155–158, 1979.CrossRefGoogle Scholar
  54. 54.
    Wolf H, Encke A, Haas S, Welzel D. Comparison of the efficacy and safety of Sandoz LMW heparin and unfractionated heparin: interim analysis of a multicenter trial. Semin Thromb Haemostas 17(Suppl 4), 343–346, 1991.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • F. Toulemonde

There are no affiliations available

Personalised recommendations